Genetic mouse models of Huntington's and Parkinson's diseases: Illuminating but imperfect

Trends in Neurosciences

Volumn 27, Issue 11, 2004, Pages 691-697

  Levine, Michael S ^a   Cepeda, Carlos ^a   Hickey, Miriam A ^a   Fleming, Sheila M ^a   Chesselet, Marie Françoise ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEHAVIOR; CELL LOSS; CLINICAL FEATURE; DISEASE COURSE; GENE IDENTIFICATION; GENETIC MODEL; HUNTINGTON CHOREA; MEDICAL INFORMATION; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; HUNTINGTON DISEASE; MICE; PARKINSON DISEASE;

EID: 5044224807     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2004.08.008     Document Type: Review

References (69)

1. J.P. Vonsattel, and M. DiFiglia Huntington disease J. Neuropathol. Exp. Neurol. 57 1998 369 384
2. Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72 1993 971 983
3. M.H. Polymeropoulos Mutation in the α-synuclein gene identified in families with Parkinson's disease Science 276 1997 2045 2047
4. A.B. Singleton Alpha-synuclein locus triplication causes Parkinson's disease Science 302 2003 841
5. M.G. Spillantini Alpha-synuclein in Lewy bodies Nature 388 1997 839 840
6. J. Hardy Genes and parkinsonism Lancet Neurol. 2 2003 221 228
7. E.M. Valente Hereditary early-onset Parkinson's disease caused by mutations in PINK1 Science 304 2004 1158 1160
8. T.M. Dawson, and V.L. Dawson Molecular pathways of neurodegeneration in Parkinson's disease Science 302 2003 819 822
9. L.B. Menalled, and M.F. Chesselet Mouse models of Huntington's disease Trends Pharmacol. Sci. 23 2002 32 39
10. D.C. Rubinsztein Lessons from animal models of Huntington's disease Trends Genet. 18 2002 202 209
11. M.A. Hickey, and M.F. Chesselet The use of transgenic and knock-in mice to study Huntington's disease Cytogenet. Genome Res. 100 2003 276 286
12. L. Mangiarini Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice Cell 87 1996 493 506
13. R.J. Carter Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation J. Neurosci. 19 1999 3248 3257
14. L.A. Lione Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation J. Neurosci. 19 1999 10428 10437
15. K.P. Murphy Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation J. Neurosci. 20 2000 5115 5123
16. V.J. Bolivar Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic mice Brain Res. 1005 2004 29 35
17. G.A. Laforet Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease J. Neurosci. 21 2001 9112 9123
18. J.G. Hodgson A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration Neuron 23 1999 181 192
19. E.J. Slow Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease Hum. Mol. Genet. 12 2003 1555 1567
20. L.B. Menalled Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice J. Neurosci. 22 2002 8266 8276
21. L.B. Menalled Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats J. Comp. Neurol. 465 2003 11 26
22. C.H. Lin Neurological abnormalities in a knock-in mouse model of Huntington's disease Hum. Mol. Genet. 10 2001 137 144
23. V.C. Wheeler Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice Hum. Mol. Genet. 11 2002 633 640
24. S.W. Davies Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation Cell 90 1997 537 548
25. A.J. Morton Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation J. Neurocytol. 29 2000 679 702
26. M. DiFiglia Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain Science 277 1997 90 1993
27. H. Li Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice Hum. Mol. Genet. 8 1999 1227 1236
28. H. Li Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice J. Neurosci. 21 2001 8473 8481
29. E. Hockly Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease Proc. Natl. Acad. Sci. U. S. A. 100 2003 2041 2046
30. M.S. Levine Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease J. Neurosci. Res. 58 1999 515 532
31. G.J. Klapstein Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice J. Neurophysiol. 86 2001 2667 2677
32. T.L. Spires Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice Eur. J. Neurosci. 19 2004 2799 2807
33. A.J. Tobin, and E.R. Signer Huntington's disease: the challenge for cell biologists Trends Cell Biol. 10 2000 531 536
34. M. Turmaine Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease Proc. Natl. Acad. Sci. U. S. A. 97 2000 8093 8097
35. C. Cepeda NMDA receptor function in mouse models of Huntington disease J. Neurosci. Res. 66 2001 525 539
36. J.A. Bibb Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice Proc. Natl. Acad. Sci. U. S. A. 97 2000 6809 6814
37. E. Sapp Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease J. Neuropathol. Exp. Neurol. 58 1999 165 173
38. V. MacDonald, and G. Halliday Pyramidal cell loss in motor cortices in Huntington's disease Neurobiol. Dis. 10 2002 378 386
39. A.J. Morton, and J.M. Edwardson Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease J. Neurochem. 76 2001 166 172
40. R. Luthi-Carter Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain Hum. Mol. Genet. 11 2002 1911 1926
41. J.C. Liévens Abnormal phosphorylation of synapsin I predicts a neuronal transmission impairment in the R6/2 Huntington's disease transgenic mice Mol. Cell. Neurosci. 20 2002 638 648
42. H. Li Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release Hum. Mol. Genet. 12 2003 2021 2030
43. C. Cepeda Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease J. Neurosci. 23 2003 961 969
44. C. Zuccato Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease Science 293 2001 493 498
45. Cepeda, C. et al. (2003) GABAergic synaptic activity and receptor expression in transgenic mouse models of Huntington's disease. Program No. 206.11 2003 Abstract Viewer and Itinerary Planner. Society for Neuroscience, Online
46. M.T. Usdin Impaired synaptic plasticity in mice carrying the Huntington's disease mutation Hum. Mol. Genet. 8 1999 839 846
47. M.M. Zeron Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease Neuron 33 2002 849 860
48. L. Li Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease Neurobiol. Aging 24 2003 1113 1121
49. R. Sattler Distinct roles of synaptic and extrasynaptic NMDA receptors in excitotoxicity J. Neurosci. 20 2000 22 33
50. G.E. Hardingham Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways Nat. Neurosci. 5 2002 405 414
51. G.P. Bates, and E. Hockly Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials? Curr. Opin. Neurol. 16 2003 465 470
52. W. Dauer, and S. Przedborski Parkinson's disease: mechanisms and models Neuron 39 2003 889 909
53. H. Braak Staging of brain pathology related to sporadic Parkinson's disease Neurobiol. Aging 24 2003 197 211
54. S. Gispert Transgenic mice expressing mutant A53T human α-synuclein show neuronal dysfunction in the absence of aggregate formation Mol. Cell. Neurosci. 24 2003 419 429
55. M. Hashimoto Transgenic models of α-synuclein pathology: past, present, and future Ann. N. Y. Acad. Sci. 991 2003 171 188
56. Fernagut, P.O. and Chesselet, M.F. Alpha-synuclein and transgenic mouse models. Neurobiol. Dis. (in press)
57. B.I. Giasson Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein Neuron 34 2002 521 533
58. M.K. Lee Human α-synuclein-harboring familial Parkinson's disease linked Ala-53→Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice Proc. Natl. Acad. Sci. U. S. A. 99 2002 8968 8973
59. H. van der Putten Neuropathology in mice expressing human α-synuclein J. Neurosci. 20 2000 6021 6029
60. E. Masliah Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders Science 287 2000 1265 1269
61. Y. Matsuoka Lack of nigral pathology in transgenic mice expressing human α-synuclein driven by the tyrosine hydroxylase promoter Neurobiol. Dis. 8 2001 535 539
62. S. Rathke-Hartlieb Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant α-synuclein transgenic mice J. Neurochem. 77 2001 1181 1184
63. E.K. Richfield Behavioral and neurochemical effects of wild-type and mutated human α-synuclein in transgenic mice Exp. Neurol. 175 2002 35 48
64. M.J. Thiruchelvam Risk factors for dopaminergic neuron loss in human α-synuclein transgenic mice Eur. J. Neurosci. 19 2004 845 854
65. H. Shimura Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase Nat. Genet. 25 2000 302 305
66. P.J. Lockhart It's a double knock-out! The quaking mouse is a spontaneous deletion of parkin and parkin co-regulated gene (PACRG) Mov. Disord. 19 2004 101 104
67. M.S. Goldberg Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons J. Biol. Chem. 278 2003 43628 43635
68. J.M. Itier Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse Hum. Mol. Genet. 12 2003 2277 2291
69. J.J. Palacino Mitochondrial dysfunction and oxidative damage in Parkin-deficient mice J. Biol. Chem. 279 2004 18614 18622